Daily Sepsis Research Analysis
Analyzed 38 papers and selected 3 impactful papers.
Summary
Across three high-impact sepsis studies, investigators identify echocardiography-defined cardiac phenotypes with prognostic value, delineate pediatric plasma proteomic signatures that persist across acute and recovery phases, and demonstrate a mechanistically defined intestinal barrier–protective strategy via PPARG activation by magnolol. Together, these works emphasize heterogeneity, complement-driven inflammation, and gut barrier modulation as converging levers for precision sepsis care.
Research Themes
- Cardiac phenotyping to guide sepsis resuscitation
- Pediatric sepsis proteomics and phase-specific biomarkers
- Gut barrier–targeted immunomodulation via PPARG
Selected Articles
1. Echocardiographic phenotypes in sepsis: identifying subgroups using latent profile analysis.
In 2,071 sepsis admissions without preexisting heart disease, latent profile analysis of echocardiography identified five cardiac phenotypes. The right-ventricular dilation with elevated tricuspid regurgitation gradient group had the highest mortality, whereas other clusters reflected diastolic dysfunction, reduced LV systolic function/low cardiac index, hyperdynamic function, or near-normal findings.
Impact: Data-driven echocardiographic phenotyping reveals prognostically distinct sepsis subgroups, offering a path toward precision resuscitation strategies beyond one-size-fits-all care.
Clinical Implications: Routine echocardiographic profiling early in sepsis could identify high-risk right-ventricular phenotypes, informing fluid, vasopressor, and ventilatory strategies that minimize RV afterload and venous congestion.
Key Findings
- Five echocardiographic phenotypes were identified using latent profile analysis in 2,071 sepsis patients.
- The right-ventricular dilation with elevated tricuspid regurgitation gradient phenotype had the highest mortality.
- Other clusters captured diastolic dysfunction (elevated E/e'), reduced LV systolic function with low cardiac index, hyperdynamic function, and near-normal findings.
- Patients met Sepsis-3 criteria; those with preexisting heart disease were excluded, and echocardiography occurred within 14 days of admission.
Methodological Strengths
- Large single-center cohort with 2,071 sepsis patients and Sepsis-3 confirmation by chart review
- Unsupervised latent profile analysis using routinely collected echocardiographic variables
Limitations
- Retrospective single-center design with potential selection bias (only patients with echocardiography included)
- No external validation or interventional testing of phenotype-guided management
Future Directions: Prospective multi-center validation and interventional trials testing phenotype-tailored resuscitation (e.g., RV-protective strategies) are warranted.
BACKGROUND: Sepsis remains a leading cause of mortality, and optimizing treatment is challenging due to patient heterogeneity. Identification of cardiac phenotypes may inform precision medicine approaches and guide resuscitation. We performed a clustering analysis of patients with sepsis using echocardiographic data without using any a priori definitions of cardiac dysfunction or outcomes to establish the subgroups. METHODS: This was a retrospective cohort study of patients admitted to the hospital with sepsis at a single academic center. Patients were identified using sepsis-related ICD codes, and those who had echocardiogram performed within 14 days of admission underwent chart review to ensure sepsis-3 criteria were met. Those with preexisting heart disease were excluded. Clustering by echocardiographic variables was performed using latent profile analysis. Clinical features such as patient characteristics, laboratory studies, sepsis source, and outcomes were compared across the clusters. RESULTS: There were 2,071 patients included in the analysis. Our cluster analysis yielded five phenotypes: cluster 1, elevated mean E/e' 24.5 (SD 9.6); cluster 2, reduced ejection fraction, mean 33.1% (SD 10.6), and cardiac index 2.6 L/min/m
2. Protective effects of magnolol, an active compound of Houpu Sanwu Tang, on intestinal barrier function in sepsis: Mechanisms of PPARG activation and inhibition of JAK-STAT and NF-κB signaling.
In vitro and CLP models showed that magnolol preserves intestinal barrier integrity by directly activating PPARG, restoring PPARG–p300/CBP interaction, and suppressing JAK-STAT and NF-κB signaling. CRISPR-mediated PPARG knockdown abrogated magnolol’s protective effects, indicating target dependence.
Impact: The study mechanistically links a defined small molecule (magnolol) to PPARG activation and dual inflammatory pathway inhibition, offering a translatable gut barrier–targeted approach in sepsis.
Clinical Implications: While preclinical, findings support evaluation of PPARG agonism (including potential repurposing) to prevent or mitigate sepsis-induced intestinal barrier failure and downstream multiorgan dysfunction.
Key Findings
- Magnolol preserved intestinal barrier integrity and reduced apoptosis/inflammation in LPS-stimulated Caco-2 cells and CLP-induced sepsis.
- Magnolol acted as a direct transcriptional activator of PPARG and restored PPARG–p300/CBP interaction suppressed by LPS.
- CRISPR-Cas9 knockdown of PPARG abrogated magnolol’s protective effects, confirming target dependence.
- PPARG activation by magnolol led to dual inhibition of proinflammatory JAK-STAT and NF-κB signaling.
Methodological Strengths
- Convergent in vitro and in vivo models (LPS-stimulated Caco-2 and CLP sepsis) with histologic and molecular readouts
- Mechanistic validation via ChIP/Co-IP and CRISPR-Cas9 knockdown of PPARG
Limitations
- Preclinical models; no human data on efficacy, safety, or pharmacokinetics
- Therapeutic window, dosing optimization, and off-target effects remain to be defined
Future Directions: Test PPARG agonists (including magnolol) in dose–response and timing studies, evaluate safety, and consider repurposing clinically approved PPARG modulators in early-phase sepsis trials.
BACKGROUND: Sepsis, a dysregulated host response to infection, frequently leads to catastrophic intestinal barrier failure, a key driver of mortality. Magnolol, a bioactive compound from Magnolia officinalis, has shown pleiotropic therapeutic effects, but its role in sepsis-induced intestinal injury remains unclear. Here, we investigate the protective mechanisms of magnolol in sepsis, focusing on its modulation of inflammatory signaling. METHODS: We employed both in vitro (LPS-stimulated Caco-2 cells) and in vivo (cecal ligation and puncture model of sepsis) systems. The effects of magnolol on cellular viability, apoptosis, inflammatory cytokine production, and intestinal barrier integrity were assessed using a combination of molecular and histological techniques, including Western blot, immunofluorescence, ChIP, and Co-IP assays. RESULTS: Magnolol potently mitigated LPS- and sepsis-induced cellular damage, apoptosis, and inflammation, while preserving intestinal barrier function. Mechanistically, we identify magnolol as a direct transcriptional activator of peroxisome proliferator-activated receptor gamma (PPARG). Magnolol treatment robustly reversed the LPS-mediated suppression of PPARG transcriptional activity (P < 0.001). This activation was crucial for its protective effects, as CRISPR-Cas9-mediated knockdown of PPARG abrogated magnolol's benefits. Furthermore, magnolol restored the physical interaction between PPARG and its co-activator p300/CBP, which was disrupted by LPS. Crucially, activation of PPARG by magnolol led to the dual inhibition of the pro-inflammatory JAK-STAT and NF-κB signaling pathways. CONCLUSION: Our study delineates a novel protective mechanism for magnolol in sepsis, demonstrating that it functions as a potent PPARG agonist to suppress the inflammatory cascade driven by the JAK-STAT and NF-κB pathways. These findings establish magnolol as a promising, mechanistically defined therapeutic candidate for treating sepsis-induced intestinal injury.
3. Plasma Proteomic Signatures of Pediatric Sepsis Reveal Persistent Inflammation and Phase-Specific Biomarkers.
Mass spectrometry proteomics across acute and recovery phases of pediatric sepsis identified 41 acute-phase proteins and persistent complement/inflammatory signatures into recovery. Machine learning nominated C9, C1R, and LRG1 as acute-phase biomarkers and S100A9 for recovery; pediatric sepsis showed enhanced alternative complement activity versus adults and distinct profiles from sterile inflammation.
Impact: Defines dynamic, phase-specific, and age-dependent protein signatures in pediatric sepsis, nominating actionable biomarkers and highlighting complement as a therapeutic axis.
Clinical Implications: Phase-specific biomarkers may aid early diagnosis, monitoring, and differentiation from sterile inflammation; complement pathway differences suggest age-tailored immunomodulatory strategies.
Key Findings
- Identified 41 differentially abundant proteins in acute pediatric sepsis versus controls, with attenuated yet persistent expression in recovery.
- Sustained enrichment of inflammatory and complement activation pathways during both acute and recovery phases.
- Machine learning highlighted C9, C1R, and LRG1 as acute-phase biomarkers and S100A9 as a recovery-phase marker.
- Compared to adults, pediatric sepsis showed enhanced alternative complement pathway activity; profiles also distinguished sepsis from sterile inflammation.
Methodological Strengths
- Mass spectrometry–based plasma proteomics with paired acute and recovery phase sampling
- Integration of cytokine profiling and machine learning feature selection
- Comparative analyses versus adult sepsis and sterile inflammation cohorts
Limitations
- Sample size and enrollment details not specified; external validation pending
- Observational proteomic associations without causal inference; clinical utility requires prospective testing
Future Directions: Validate biomarker panels in multi-center cohorts, assess prognostic/theranostic value, and explore age-tailored complement modulation.
Sepsis remains a leading cause of pediatric morbidity and mortality, yet its molecular underpinnings are poorly understood. Here, we performed mass spectrometry-based plasma proteomics and cytokine profiling in pediatric sepsis patients at the acute phase (AP) and recovery phase (RP), alongside preoperative surgical controls. In AP vs. control, we identified 41 differentially abundant (DA) proteins, including acute-phase reactants and complement factors, with persistent but attenuated expression in RP. Pathway analysis revealed sustained enrichment in inflammatory and complement activation processes during both AP and RP, with partial restoration of immune surveillance and vascular homeostasis in recovery. Machine learning highlighted complement components (C9, C1R) and LRG1 as candidate AP biomarkers, and S100A9 as an RP-associated marker. Comparative analysis with adult sepsis proteomes uncovered age-specific complement activation patterns: adults displayed higher classical pathway activity, whereas pediatric patients exhibited enhanced alternative pathway activity. Cytokine profiling confirmed sustained immune activation and endothelial perturbation across sepsis phases. We also compared the sepsis cohort with the sterile inflammation (SI) cohort, which revealed distinct adaptive immune enrichment in sepsis while innate immune predominance in SI, enabling the identification of potential sepsis-specific protein signatures. Together, these findings delineate the dynamic immune and vascular proteomic landscape of pediatric sepsis, reveal biomarkers distinguishing sepsis from sterile inflammation, and highlight age-related complement pathway differences with potential therapeutic implications.